{'fraction_non_alphanumeric': 0.05315947843530592, 'fraction_numerical': 0.015045135406218655, 'mean_word_length': 6.028169014084507, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Complementary analyses of the AMBAR trial: Impact of discontinuations, consistency of results across outcomes and additional adjustments

The AMBAR study enrolled 496 mild‐to‐moderate Alzheimer’s disease (AD) patients from Spain and US centers, 347 of which were randomized [1:1:1:1] to three treatment arms of plasma exchange (PE) with different doses of albumin with or without intravenous immunoglobulin (IVIG) or placebo (sham PE) arm. PE treatment showed slow cognitive and functional decline in AD patients, with variable significance in outcome (primary: ADCS‐ADL, ADAS‐Cog; secondary: CDR‐Sb, ADCS‐CGIC), baseline disease severity, and treatment arm (low‐albumin; low‐albumin+IVIG, high‐albumin+IVIG, and all three combined). The percentage of patient dropouts ranged from 20% in the placebo to 34.9% in the low‐albumin+IVIG group. In this analysis we investigated the effect of possible biases due to discontinuations and baseline imbalances, and assessed the consistency across outcomes.